Micro-cap neurodevelopment biotech PaxMedica sets terms for $15 million IPO

PaxMedica, a Phase 2 biotech developing therapies for neurodevelopmental disorders, announced terms for its IPO on Thursday.

The Woodcliff Lake, NJ-based company plans to raise $15 million by offering 2.5 million shares at a price range of $5.50 to $6.50. At the midpoint of the proposed range, PaxMedica would command a fully diluted market value of $64 million.

The company's lead candidate PAX-101, an intravenous formulation of suramin, is currently in a Phase 2B clinical trial at six sites in South Africa for the treatment of autism spectrum disorder (ADS), which affects more than 3.5 million Americans.

PaxMedica was founded in 2018 and plans to list on the Nasdaq under the symbol PXMD. The Benchmark Company is the sole bookrunner on the deal.

The article Micro-cap neurodevelopment biotech PaxMedica sets terms for $15 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest IPOs Videos

Nordic Listings End of Year Sizzle Reel

Jan 18, 2022

Renaissance Capital

Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

Learn More